Form 4: Apogee Therapeutics' Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold shares of common stock on October 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 2, 2024, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 27, 2023.
• A total of 5,740 shares were sold at a weighted average price of $56.16, with individual prices ranging from $55.62 to $56.60.
• An additional 925 shares were sold at a weighted average price of $56.86, with individual prices ranging from $56.64 to $57.15.
• Following these transactions, Dambkowski directly owns 274,128 shares of Apogee Therapeutics' common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports the sale of shares under a pre-arranged trading plan, which is a common practice. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Sales by company insiders are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading. The market typically views these sales in the context of the overall financial health and prospects of the company.

Comparison to Industry Standards

• Insider sales are a common practice across the pharmaceutical and biotech industries.
• Companies like Amgen, Regeneron, and Gilead Sciences often see similar filings from their executives.
• The volume and frequency of these sales are generally compared to historical insider trading patterns within the specific company and among its peers to assess whether the activity is routine or indicative of a change in sentiment.

Stakeholder Impact

• The sale of shares by a company officer could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates